0000880771-16-000177.txt : 20160816 0000880771-16-000177.hdr.sgml : 20160816 20160816173206 ACCESSION NUMBER: 0000880771-16-000177 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160812 FILED AS OF DATE: 20160816 DATE AS OF CHANGE: 20160816 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Meng Chuncai CENTRAL INDEX KEY: 0001600522 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 161836950 MAIL ADDRESS: STREET 1: 30F SHANGHAI TIMES SQUARE STREET 2: NO. 93 HUAI HAI ROAD CITY: SHANGHAI STATE: F4 ZIP: 200021 4 1 certent-form4.xml PRIMARY DOCUMENT X0306 4 2016-08-12 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001600522 Meng Chuncai 950 TOWER LANE, SUITE 200 FOSTER CITY CA 94404 0 1 0 0 Gen. Counsel & VP Compliance Common Stock 2016-08-12 4 M 0 23333 4.52 A 23333 D Common Stock 2016-08-12 4 S 0 23333 10.41 D 0 D Common Stock 2016-08-12 4 M 0 7000 8.83 A 7000 D Common Stock 2016-08-12 4 S 0 7000 10.41 D 0 D Common Stock 2016-08-12 4 M 0 750 0 A 750 D Common Stock 2016-08-12 4 S 0 750 10.41 D 0 D Non-Qualified Stock Options (right to buy) 4.52 2016-08-12 4 M 0 23333 0 D 2024-03-14 Common Stock 23333 30000 D Non-Qualified Stock Options (right to buy) 8.83 2016-08-12 4 M 0 7000 0 D 2025-03-16 Common Stock 7000 14000 D Restricted Stock Unit 2016-08-12 4 M 0 750 0 D Common Stock 750 5250 D Granted under the Issuer's 2005 Equity Incentive Plan. 25% of such shares vest on February 9, 2015 and 2.0833% vests each month thereafter provided that the Reporting Person continues to be employed by the Issuer. 25% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer. Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock. Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment. /s/ Friedhelm Blobel, Attorney-in-Fact For Chuncai Meng 2016-08-16